Back to results
US 2026/0227413 A1Published application
Uses of il-40 and methods for detecting il-40 activity
AssigneeBiolegend, Inc.
InventorsMarcela Hernandez Ruiz, Gerardo Arrevillaga Boni, David Michael Soper
Life of this patent
Estimating the term…
Abstract
The technology relates in part to methods for detecting the activity of IL-40 and modified versions thereof. The technology also relates in part to uses of IL-40 for promoting cell differentiation.
Claims21
-144. (canceled)
A kit, comprising:
- a) a first composition comprising one more polypeptides chosen from Interferon-gamma (IFN-γ), granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon-alpha (IFN-α), interleukin 1 beta (IL-1), interleukin 4 (IL-4), interleukin 10 (IL-10), interleukin 13 (IL-13), macrophage colony-stimulating factor (M-CSF), transforming growth factor beta (TGF-0), and tumor necrosis factor alpha (TNF-α);
- b) a second composition comprising an Interleukin 40 (IL-40) polypeptide;
- b) one or more components for measuring cytokine, chemokine, and/or growth factor production, wherein the cytokines, chemokines, and/or growth factors are chosen from one or more of chemokine (C-C motif) ligand 2 (CCL2), chemokine (C-C motif) ligand 3 (CCL3), chemokine (C-C motif) ligand 4 (CCL4), chemokine (C-C motif) ligand 5 (CCL5), chemokine (C-C motif) ligand 11 (CCL11), chemokine (C-C motif) ligand 17 (CCL17), chemokine (C-C motif) ligand 20 (CCL20), chemokine (C-X-C motif) ligand 1 (CXCL1), chemokine (C-X-C motif) ligand 5 (CXCL5), chemokine (C-X-C motif) ligand 8 (CXCL8), chemokine (C-X-C motif) ligand 9 (CXCL9), chemokine (C-X-C motif) ligand 10 (CXCL10), chemokine (C-X-C motif) ligand 11 (CXCL11), interleukin-1 receptor antagonist (IL-1RA), IL-6, erythropoietin, platelet derived growth factor AA (PDGF-AA), and vascular endothelial growth factor (VEGF);
- and
- c) instructions for use.
2 more elements
A method for characterizing IL-40 expression on a cell, comprising:
- a) contacting the cell with a first composition comprising a stimulant;
- b) contacting the cell with a second composition comprising an IL-40 polypeptide and a fusion tag or detectable label under conditions to bind said second composition to an IL-40 receptor on the cell, wherein the binding generates the production of a receptor/IL-40 polypeptide complex;
- c) detecting the receptor/IL-40 polypeptide complex;
- wherein the complex comprises cytokines, chemokines, and/or growth factors and wherein the one or more cytokines, chemokines, and/or growth factors is selected from the group consisting of chemokine (C-C motif) ligand 2 (CCL2), chemokine (C-C motif) ligand 3 (CCL3), chemokine (C-C motif) ligand 4 (CCL4), chemokine (C-C motif) ligand 5 (CCL5), chemokine (C-C motif) ligand 11 (CCL11), chemokine (C-X-C motif) ligand 8 (CXCL8), chemokine (C-X-C motif) ligand 10 (CXCL10), interleukin-1 receptor antagonist (IL-1RA), erythropoietin, platelet derived growth factor AA (PDGF-AA) and vascular endothelial growth factor (VEGF);
- and
- d) characterizing the cell based on the detection of the receptor/IL-40 polypeptide complex the cell.
3 more elements
A kit for assessing activity of an IL-40 polypeptide in a sample, comprising:
- a) a population of monocytes;
- b) a first comprising an IL-40 polypeptide;
- c) an analysis device comprising a surface;
- d) means for measuring monocyte to macrophage differentiation in the population;
- and
- e) instructions for use.
3 more elements
Dependencies are inferred from the claim text.